X
<

Where Is Novartis Positioned after 3Q17?

PART:
1 2 3 4 5 6 7 8 9 10 11 12
Part 4
Where Is Novartis Positioned after 3Q17? PART 4 OF 12

Inside Novartis’s Ophthalmology Drugs Now

Lucentis revenue trends

In 3Q17, Novartis’s (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).

The market expansion of Lucentis in Europe, Japan, and emerging markets in addition to a reimbursement listing in China for use in wet age-related macular degeneration (or wAMD) primarily attributed to the revenue growth of Lucentis in 3Q17. Lucentis (ranibizumab) faces competition from Regeneron Pharmaceuticals’ (REGN) Eylea.

Inside Novartis’s Ophthalmology Drugs Now

Interested in NVS? Don't miss the next report.

Receive e-mail alerts for new research on NVS

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Travoprost Group revenue trends

In 3Q17, Travoprost generated revenues of ~$149 million, which was ~1% higher YoY and 5% higher QoQ. The loss of exclusivity in Europe primarily attributed to the decline in Travoprost’s sales in 3Q17.

The Travoprost group consists of Travatan, TravatanZ, and DuoTrav. These drugs are used to decrease intraocular pressure in individuals with open-angle glaucoma. In the marketplace, Travoprost faces stiff competition from Pfizer’s (PFE) Xalatan and Allergan’s (AGN) Lumigan.

Systane Group revenue trends

In 3Q17, the Systane Group of drugs generated revenues of $100 million, which was ~4% higher YoY but ~4% lower QoQ.

The Systane group consists of Systane Ultra, Systane Balance, and Systane Hydration. In 3Q17, Systane sales witnessed growth in the US market, but this was offset by a modest decline in European markets.

Topical Olopatadine Group

In 3Q17, Olopatadine group reported revenues of $49 million, which was ~40% lower YoY and 36% lower QoQ. The loss of market exclusivity in the US for Pataday primarily attributed to the decline in the Olopatadine group’s revenues.

The Olopatadine group consists of Patanol, Pataday, and Pazeo—all of which are olopatadine ophthalmic solutions of different concentrations.

In 3Q17, Novartis’s (NVS) Ophthalmology drugs generated revenues of $1.3 billion, which was ~3% lower YoY and ~4% lower QoQ.

Notably, the Vanguard International Dividend Appreciation ETF (VIGI) invests 2.48% of its total portfolio holdings in Novartis.

X

Please select a profession that best describes you: